Mimetogen
Montreal, CA · 1 known investors
Mimetogen Pharmaceuticals is a late-stage clinical biotechnology company developing synthetic neurotrophin mimetics to treat ocular surface and retinal diseases. Its lead compound, tavilermide, is being evaluated in Phase 3 studies for dry eye disease, and it is also pursuing therapies for degenerative retinal conditions such as retinitis pigmentosa.</parameter> <parameter name="founders">[]
Investors · 1
In the news
Frequently asked questions
- What does Mimetogen do?
- Mimetogen Pharmaceuticals is a late-stage clinical biotechnology company developing synthetic neurotrophin mimetics to treat ocular surface and retinal diseases. Its lead compound, tavilermide, is being evaluated in Phase 3 studies for dry eye disease, and it is also pursuing therapies for degenerative retinal conditions such as retinitis pigmentosa.</parameter> <parameter name="founders">[]
- Who are Mimetogen's investors?
- Mimetogen's investors include Schooner Capital.
- Where is Mimetogen headquartered?
- Mimetogen is headquartered in Montreal, CA.